Abstract:Background COVID-19 is a new and highly contagious respiratory disease that has caused global spread, high case fatality rate in severe patients, and a huge medical burden due to invasive mechanical ventilation. The current diagnosis and treatment guidelines are still need to be improved, and more excellent clinical experience is needed to provide reference. Methods We analyzed and summarized clinical data of 97 confirmed COVID-19 adult patients (including 26 severe cases) admitted to the Fifth Affiliated Hospital of Sun Yat-sen University from January 17, 2020 to March 10, 2020, included laboratory examination results, imaging findings, treatment effect, prognosis, etc, in order to put forward prediction index of severe COVID-19 patients, principles of early intervention and methylprednisolone usages in COVID-19 patients. Results 1. Hypoxemia, hyperlactic acid, hypoproteinemia, and hypokalemia were prevalent in COVID-19 patients. The significant low lymphocyte count, hypoproteinemia, hypokalemia, the persistent or worsen high CRP, high D-dimer, and high BNP, and the occurrence of hemoptysis and novel coronavirus (SARS-CoV-2) viremia were important indicators for early diagnosis and prediction of severe disease progression. 2. Characteristic images of lung CT had a clear change in COVID-19, Ground-glass opacity (GGO) and high-density linear combinations may indicate different pathological changes. Rapid lobular progression of GGO suggests the possibility of severe disease. 3. Basic principles of early intervention treatment of COVID-19: on the premise of no effective antiviral drugs, treatment is based on supportive and symptomatic therapy (albumin supplementation, supplement of potassium, supplement blood plasma, etc.) in order to maintain the stability of the intracellular environment and adequately reactivate body immunity to clean up SARS-CoV-2. 4. According to severity, oxygenation index, body weight, age, underlying diseases, appropriate amount methylprednisolone application on severe/critical COVID-19 patients on demand, improved blood oxygen and reduced the utilization rate of invasive mechanical ventilation, case fatality rate and medical burden significantly. The most common indications for invasive mechanical ventilation should be strictly control in critical COVID-19 patients. Conclusions 1. Accurate and timely identification of clinical features in severe risks, and early and appropriate intervention can block disease progression. 2. Appropriate dose of methylprednisolone can effectively avoid invasive mechanical ventilation and reduce case fatality rate in critical COVID-19 patients. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial This study is a retrospective observational study, so we do not need a trial ID ### Funding Statement NO funding ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The readers can access the data supporting the conclusions of the study in the manuscript and updated manuscript if the data has been updated

The Role of Methylprednisolone on Preventing Disease Progression for Hospitalized Patients with Severe COVID‐19

Evaluating the Efficacy and Side Effects of Corticosteroid Therapy in Severely ill COVID-19 Patients

The Role of Methylprednisolone in Severe COVID-19 Patients: a Meta-Analysis

Effect of methylprednisolone in reducing severe COVID-19 and mortality in high-risk patients: A retrospective study

Effect of Methylprednisolone Therapy on Hospital Stay and Viral Clearance in Patients with Moderate COVID-19

Efficacy and Safety of Glucocorticoids in Treatment of COVID-19: a Retrospective Study.

The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study

Corticosteroid Therapy in Critically Ill Patients with COVID-19: a Multicenter, Retrospective Study

Clinical Efficacy Of Methylprednisolone And The Combined Use Of Lopinavir/Ritonavir With Arbidol In Treatment Of Coronavirus Disease 2019

Effect of methylprednisolone treatment on COVID-19: An inverse probability of treatment weighting analysis

Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: a retrospective cohort study

Methylprednisolone Was Associated with Reduced In-Hospital Mortality in COVID-19 Patients with Low Lymphocyte Counts: a Multicenter Retrospective Propensity Analysis

Hypersensitivity in the Lungs is Responsible for Acute Respiratory Failure in COVID‐19 Patients: Case Series of Patients Who Received High‐dose/short‐term Methylprednisolone

Efficacy and safety of glucocorticoids in the treatment of COVID-19: a systematic review and meta-analysis of RCTs

Key to successful treatment of COVID 19: accurate identification of severe risks and early intervention of disease progression

Evaluation of the Efficacy of Methylprednisolone Pulse Therapy in Treatment of Covid-19 Adult Patients with Severe Respiratory Failure: Randomized, Clinical Trial

Effects of Different Corticosteroid Therapy on Severe COVID-19 Patients: a Meta-Analysis of Randomized Controlled Trials

Application of Glucocorticoids in Treatment of COVID-19

A comparative study between methylprednisolone versus dexamethasone as an initial anti-inflammatory treatment of moderate COVID-19 pneumonia: an open-label randomized controlled trial

Dosage and utilization of dexamethasone in the management of COVID-19: A critical review

Temporal patterns of cytokine and injury biomarkers in hospitalized COVID-19 patients treated with methylprednisolone